2009
Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers.
Pusztai L, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Symmans W, Andre F, de The H, Coutant C, Coutant C. Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers. Cancer Research 2009, 69: 6122-6122. DOI: 10.1158/0008-5472.sabcs-09-6122.Peer-Reviewed Original ResearchDistant metastasis-free survivalP53 signatureBreast cancerER- cancersPredictive valueWorse distant metastasis-free survivalSystemic adjuvant therapyER- breast cancerMetastasis-free survivalNegative breast cancerDifferent molecular subtypesP53 functional statusP53 gene mutationsGene expression-based predictorsP53 mutation statusAdjuvant tamoxifenAdjuvant therapyFree survivalBackgroundBreast cancerFunctional statusMolecular subtypesIndependent cohortNeoplastic diseaseChemotherapy sensitivityMutation status
2006
Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer
Holmes F, O’Shaughnessy J, Hellerstedt B, Pippen J, Vukelja S, Kocs D, Asmar L, Fenske E, Lin F, Symmans W, Pusztai L. Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer. Journal Of Clinical Oncology 2006, 24: 10595-10595. DOI: 10.1200/jco.2006.24.18_suppl.10595.Peer-Reviewed Original Research